NGS-Based Diagnosis of Treatable Neurogenetic Disorders in Adults: Opportunities and Challenges.

Details

Ressource 1Download: genes-12-00695.pdf (1262.92 [Ko])
State: Public
Version: author
License: CC BY 4.0
Serval ID
serval:BIB_EF75CA328A1A
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
Title
NGS-Based Diagnosis of Treatable Neurogenetic Disorders in Adults: Opportunities and Challenges.
Journal
Genes
Author(s)
Good J.M., Atallah I., Castro Jimenez M., Benninger D., Kuntzer T., Superti-Furga A., Tran C.
ISSN
2073-4425 (Electronic)
ISSN-L
2073-4425
Publication state
Published
Issued date
06/05/2021
Peer-reviewed
Oui
Volume
12
Number
5
Pages
695
Language
english
Notes
Publication types: Case Reports
Publication Status: epublish
Abstract
The identification of neurological disorders by next-generation sequencing (NGS)-based gene panels has helped clinicians understand the underlying physiopathology, resulting in personalized treatment for some rare diseases. While the phenotype of distinct neurogenetic disorders is generally well-known in childhood, in adulthood, the phenotype can be unspecific and make the standard diagnostic approach more complex. Here we present three unrelated adults with various neurological manifestations who were successfully diagnosed using NGS, allowing for the initiation of potentially life-changing treatments. A 63-year-old woman with progressive cognitive decline, pyramidal signs, and bilateral cataract was treated by chenodeoxycholic acid following the diagnosis of cerebrotendinous xanthomatosis due to a homozygous variant in CYP27A1. A 32-year-old man with adult-onset spastic paraplegia, in whom a variant in ABCD1 confirmed an X-linked adrenoleukodystrophy, was treated with corticoids for adrenal insufficiency. The third patient, a 28-year-old woman with early-onset developmental delay, epilepsy, and movement disorders was treated with a ketogenic diet following the identification of a variant in SLC2A1, confirming a glucose transporter type 1 deficiency syndrome. This case study illustrates the challenges in the timely diagnosis of medically actionable neurogenetic conditions, but also the considerable potential for improving patient health through modern sequencing technologies.
Keywords
ATP Binding Cassette Transporter, Subfamily D, Member 1/genetics, Adrenoleukodystrophy/diagnosis, Adrenoleukodystrophy/genetics, Adult, Carbohydrate Metabolism, Inborn Errors/diagnosis, Carbohydrate Metabolism, Inborn Errors/genetics, Cholestanetriol 26-Monooxygenase/genetics, Female, Genetic Testing/methods, Glucose Transporter Type 1/genetics, High-Throughput Nucleotide Sequencing/methods, Humans, Male, Middle Aged, Monosaccharide Transport Proteins/deficiency, Monosaccharide Transport Proteins/genetics, Sequence Analysis, DNA/methods, Xanthomatosis, Cerebrotendinous/diagnosis, Xanthomatosis, Cerebrotendinous/genetics, X-linked adrenoleukodystrophy, cerebrotendinous xanthomatosis, glucose transporter type 1 deficiency syndrome, neurogenetic disorders, next-generation sequencing (NGS), treatable diseases
Pubmed
Web of science
Open Access
Yes
Create date
21/05/2021 10:43
Last modification date
22/04/2023 5:50
Usage data